Goldman Sachs’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Goldman Sachs’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-156,113	Closed	-$8.59M	–	6860
2022 Q2	$8.59M	Sell	156,113 -284,892	-65%	-$14.9M	﹤0.01%	2661
2022 Q1	$14.1M	Buy	+441,005	New	+$12.7M	﹤0.01%	2348
2018 Q4	–	Sell	-1,014	Closed	-$69K	–	5825
2018 Q3	$69K	Sell	1,014 -2,879	-74%	-$261K	﹤0.01%	5230
2018 Q2	$461K	Buy	3,893 +1,675	+76%	+$168K	﹤0.01%	4556
2018 Q1	$184K	Buy	+2,218	New	+$251K	﹤0.01%	5038
2017 Q1	–	Sell	-998	Closed	-$59K	–	7087
2016 Q4	$59K	Buy	998 +723	+263%	+$45.1K	﹤0.01%	6342
2016 Q3	$20K	Buy	+275	New	+$21.3K	﹤0.01%	6762
2016 Q2	–	Sell	-1,094	Closed	-$295K	–	7337
2016 Q1	$295K	Buy	1,094 +596	+120%	+$190K	﹤0.01%	5280
2015 Q4	$299K	Buy	498 +66	+15%	+$44.7K	﹤0.01%	5355
2015 Q3	$354K	Buy	+432	New	+$487K	﹤0.01%	5462

Other funds holding SRRA

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Goldman Sachs's SRRA Position: Q3 2022 in Review

Goldman Sachs sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 156,113 shares — an estimated $8.59M sold.

Goldman Sachs first reported a position in SRRA in Q3 2015 and held it in 10 quarters. The position peaked at $14.1M in Q1 2022. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.

Goldman Sachs reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Goldman Sachs sold 156,113 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $8.59M.
Goldman Sachs first reported a position in Sierra Oncology, Inc. Common Stock in Q3 2015 and held it in 10 quarters.
Goldman Sachs's Sierra Oncology, Inc. Common Stock position peaked at $14.1M in Q1 2022.
1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.

Based on Goldman Sachs's 13F filing for Q3 2022, filed 14 Nov 2022.